IOL Chemicals and Pharmaceuticals Limited — Updates, 07-08-2025: Press Release

IOL Chemicals & Pharma (IOLCP) reported robust Q1 FY26 financial results. Revenue increased 9.8% to ₹551.7 Cr, EBITDA rose 19.5% to ₹69.5 Cr, and PAT grew 14.4% to ₹34.0 Cr. This strong performance was achieved despite challenging market conditions. Operational highlights include securing REACH registration for Acetic Anhydride, which opens exports to EU markets. The company also initiated a ₹5.5 Cr project for a new Minoxidil manufacturing unit, expected by December 2025. IOLCP is seeing strong traction in non-Ibuprofen APIs and has commissioned its backward-integrated Paracetamol unit, expanding its global footprint.